Access optionsAccess options
Subscribe to Journal
Get full journal access for 1 year
only $17.75 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Frankel S et al. (2003) Screening for prostate cancer. Lancet 361: 1122–1128
Stanford JL et al. (2000) Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the prostate cancer outcomes study. JAMA 283: 354–360
The UK National Screening Committee (NSC) [http://www.nsc.nhs.uk/uk_nsc/uk_nsc_ind.htm]
McGregor M et al. (1998) Screening for prostate cancer: estimating the magnitude of overdetection. CMAJ 159: 1368–1372
Draisma G et al. (2003) Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 95: 868–878
Gann PH et al. (1995) A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 273: 289–294
Hakama M et al. (2001) Validity of the prostate specific antigen test for prostate cancer screening: followup study with a bank of 21,000 sera in Finland. J Urol 166: 2189–2191
Thompson IM et al. (2004) Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter. N Engl J Med 350: 2239–2246
Thompson IM et al. (2005) Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 294: 66–70
Bill-Axelson A et al. (2005) Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 352: 1977–1984
Oliver SE et al. (2000) Comparison of trends in prostate-cancer mortality in England and Wales and the USA. Lancet 355: 1788–1789
Lu-Yao G et al. (2002) Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. Br Med J 325: 740
Richard M Martin and Jenny Donovan are principal investigators on a randomized controlled trial of the potential population impact of PSA testing for prostate cancer in the UK (Comparison arm for ProtecT trial, CAP), funded by Cancer Research UK/UK Department of Health, and the NHS Health Technology Assessment Programme.
About this article
Population-based prostate-specific antigen testing in the UK leads to a stage migration of prostate cancer
BJU International (2009)
Cancer Causes & Control (2008)
BJU International (2008)
Impact of PSA Screening on the Incidence of Advanced Stage Prostate Cancer in the United States: A Surveillance Modeling Approach
Medical Decision Making (2008)
International Journal of Epidemiology (2007)